Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 1, p. s303, 2024. DOI: 10.25251/skin.8.supp.303. Disponível em: https://skin.dermsquared.com/skin/article/view/2436. Acesso em: 22 jul. 2025.